Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.49 |
| ▸ | IGF1R | P08069 | 10/20 | 0.41 |
| ▸ | PAK4 | O96013 | 2/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13054592 | 0.88 | IGF1R (0.49) | SRCGSK3BAURKBIGF1RNTRK1 | |
| SCHEMBL13054595 | 0.86 | IGF1R (0.46) | SRCGSK3BAURKBIGF1RAURKA | |
| SCHEMBL13054569 | 0.86 | GSK3B (0.65) | SRCGSK3BAURKBPAK4PAK1 | |
| SCHEMBL14423346 | 0.83 | SRC (0.49) | SRCGSK3BAURKBIGF1RPAK4 | |
| SCHEMBL13054580 | 0.83 | AURKB (0.49) | SRCGSK3BAURKBIGF1RPAK4 | |
| SCHEMBL12430795 | 0.82 | AURKA (0.55) | SRCGSK3BAURKBIGF1RAURKA | |
| SCHEMBL13054646 | 0.81 | PAK4 (0.49) | AURKBIGF1RPAK4PAK1AURKA | |
| SCHEMBL13054745 | 0.80 | IGF1R (0.45) | SRCGSK3BIGF1RPAK4PAK1 | |
| SCHEMBL13054590 | 0.80 | IGF1R (0.47) | SRCGSK3BAURKBIGF1RAURKA | |
| SCHEMBL13054692 | 0.79 | AURKB (0.41) | SRCGSK3BAURKBIGF1RPAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842712-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842712-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
| US-7262200-B2 | Indazolinone compositions useful as kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048250-A1 | INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS | LCK, CDK2, MKNK2 | SRC 99/4885GSK3B 28/4885AURKB 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.